Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Withdrawn 1

Sponsor Class

OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Recurrence 1Hepatitis C, Chronic 1Carcinoma, Hepatocellular 1

Interventions

Metformin 3Letrozole 3Sperm Injections, Intracytoplasmic 2Progesterone 2Lidocaine 2Indocyanine Green 2Gentamicins 2Estradiol 2Clomiphene 2Bevacizumab 2Acitretin 2tirbanibulin 1technetium Tc 99m nanocolloid 1suvorexant 1pomalidomide 1pembrolizumab 1pasireotide 1nilotinib 1methylnaltrexone 1ledipasvir 1ixazomib 1gadolinium ethoxybenzyl DTPA 1gadofosveset trisodium 1exemestane 1encorafenib 1dolutegravir 1ceftolozane, tazobactam drug combination 1binimetinib 1bicalutamide 1apatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Withdrawn × ledipasvir × Clear all
NCT02959359 2017-08-07

DAA in the Risk of Recurrence After Curative Treatment of HCC

Taipei Veterans General Hospital, Taiwan

Phase 4 Withdrawn
Gastrointestinal

Carcinoma, Hepatocellular, Recurrence, Hepatitis C, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡